Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07402915 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Enrollment increased: 24 → 32 participants Eligibility criteria expanded, about 7 words · Secondary endpoints: details revised at 2 of 11 entries · Site details revised at 3 of 9 sites · 1 more Show 4 more changesShow less
    • Eligibility criteria expanded, about 7 words
    • Secondary endpoints: details revised at 2 of 11 entries
    • Site details revised at 3 of 9 sites
    • Study description expanded, about 5 words
  2. 2 versions Re-verified since May 19, 2026, no change to tracked fieldsv3-v4
  3. Primary and study completion dates: Oct 22, 2027 to Oct 15, 2027 Site details revised at 3 of 9 sitesv2 Show 1 more changeShow less
    • Site details revised at 3 of 9 sites
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
AstraZeneca
727 trials monitored
See 61 trials at risk
Ovarian Cancer
1,245 trials monitored
See 80 trials at risk
The purpose of this study is to assess the effect of itraconazole on the pharmacokinetics (PK) of AZ14170132.
Trial Details
NCT Number NCT07402915
Lead Sponsor AstraZeneca
Conditions Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal
Enrollment 32 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov